SHANGHAI

上海

,

，

March 5, 2025

2025年3月5日

/PRNewswire/ -- SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative clinical-stage bispecific antibody drugs. The launch of this product series will provide robust support for the development of bispecific antibody drugs, helping to overcome critical challenges in drug development..

/PRNewswire/ -- 三优生物今日宣布正式推出73种全系列双特异性抗体参考品，涵盖全球已获批及具有代表性的临床阶段双特异性抗体药物。该系列产品将为双特异性抗体药物的开发提供有力支持，助力解决药物开发中的关键挑战。

The development of bispecific antibody drugs is at the forefront of antibody research. Compared to monoclonal antibodies, bispecific antibody drugs can simultaneously bind to two different antigens or epitopes, theoretically leveraging the synergistic effects of dual targets, thereby overcoming limitations such as drug resistance associated with single-target therapies.

双特异性抗体药物的发展处于抗体研究的前沿。与单克隆抗体相比，双特异性抗体药物可以同时结合两种不同的抗原或表位，理论上利用双靶点的协同作用，从而克服单靶点治疗相关的耐药性等局限性。

By the end of 2024, 19 bispecific antibody drugs have been approved globally, with hundreds more in development. This number is expected to continue growing by 2025. According to Market.us, the global bispecific antibody drug market is projected to grow at a compound annual growth rate (CAGR) of 37.5% from 2024 to 2033, reaching a market size of hundreds of billions of dollars by 2033..

截至2024年底，全球已批准19种双特异性抗体药物上市，还有数百种正在开发中。预计到2025年，这一数字还将继续增长。根据Market.us的数据，从2024年到2033年，全球双特异性抗体药物市场预计将以37.5%的年均复合增长率（CAGR）增长，到2033年市场规模将达到数千亿美元。

Bispecific antibody drugs hold significant clinical value and market demand. Leveraging its self-developed high-quality bispecific antibody preparation platform, SanyouBio has successfully prepared 73 bispecific reference antibody products, covering all approved and representative clinical-stage bispecific antibody drugs.

双特异性抗体药物具有重要的临床价值和市场需求。三优生物利用其自主研发的高品质双特异性抗体制备平台，已成功制备73个双特异性对照抗体产品，涵盖所有已上市及具有代表性的临床阶段双特异性抗体药物。

These products were officially launched on .

这些产品正式发布于 。

March 5, 2025

2025年3月5日

.

。

As a core product of SanyouBio, the bispecific reference antibody products encompass dozens of configurations, including CrossMab, Duobody, BiTE, DRAT, and Fab. Each configuration has undergone rigorous quality control and data validation to ensure superior binding affinity and stability. These reference products are not only suitable for early-stage drug screening but also for preclinical efficacy evaluation..

作为三优生物的核心产品，双特异性参考抗体产品涵盖了数十种结构形式，包括CrossMab、Duobody、BiTE、DRAT以及Fab。每种结构形式均经过严格的质量控制和数据验证，确保具备优越的亲和力和稳定性。这些参考抗体产品不仅适用于早期药物筛选，还能够用于临床前药效评估。

In addition to bispecific antibody reference products, SanyouBio has developed a one-stop bispecific design application called OneClick+, which integrates over 150 antibody configuration diagrams, covering four major categories: classic bispecific antibodies, nanobodies, ScFv, and complex antibodies.

除了双特异性抗体参考产品外，三优生物还开发了一站式双特异性设计应用OneClick+，该应用整合了150多种抗体配置图，涵盖了四大类：经典双特异性抗体、纳米抗体、单链抗体可变区（ScFv）和复杂抗体。

This application meets the demanding needs of bispecific antibody design, providing strong technical support for the personalized design of bispecific antibody drugs..

该应用满足双特异性抗体设计的高要求需求，为双特异性抗体药物的个性化设计提供了强有力的技术支持。

Dr. Lang Guojun, CEO of SanyouBio, stated: 'The launch of these bispecific antibody reference products marks a significant milestone in SanyouBio's exploration of the bispecific drug development field, reflecting our commitment to advancing the global biopharmaceutical industry. SanyouBio will continue to dedicate itself to the research and innovation of bispecific antibody drugs, optimizing our products and services to support the growth of the global biopharmaceutical sector.

三优生物首席执行官郎国俊博士表示：“这些双特异性抗体参考品的推出标志着三优生物在双特异性药物开发领域的探索迈出了重要的一步，体现了我们推动全球生物制药行业发展的承诺。三优生物将继续致力于双特异性抗体药物的研究与创新，优化我们的产品和服务，以支持全球生物制药领域的成长。”

In the future, SanyouBio plans to further expand the product line of bispecific antibody reference products and continuously upgrade bispecific antibody design applications like OneClick+ to provide more comprehensive and efficient solutions for our clients. Together, we will advance the clinical application and commercialization of bispecific antibody drugs, paving the way for a brighter future.'.

未来，三优生物计划进一步拓展双特异性抗体参比品的产品线，持续升级OneClick+等双特异性抗体设计应用，为客户提供更全面、高效的解决方案。我们将共同推动双特异性抗体药物的临床应用与商业化进程，为开创更加美好的未来铺平道路。

About Sanyou Bio

关于三友生物

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate 'differentiated CRO, integrated CDO, innovative CPO and characteristic CRS', to accomplish the mission 'to make the R&D easy for innovative biologics'..

三优生物医药（上海）有限公司是一家专注于创新生物药物研发和服务的世界领先的高新技术企业。三优生物构建了“差异化CRO、整合型CDO、创新型CPO、特色CRS”四位一体的4C业务模式，致力于实现“让创新生物药研发更轻松”的使命。

Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by 'super-trillion, integration, and intelligence' , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc..

三优建立了设施先进的创新型生物药物一体化研发实验室，并拥有以博士和硕士为主的专业团队，构建了“超万亿、一体化、智能化”三大行业领先的创新技术平台，包含50多个子平台，以核心创新的超万亿噬菌体展示平台为基础，依托材料制备、生物药物发现、分子优化、体内外药效、生产细胞株构建、上下游工艺开发、临床前研发、产业化开发等平台支撑。

Sanyou's business network has expanded to all parts of the world, including

三友的业务网络已经扩展到世界各地，包括

Asia

亚洲

, US and

，美国和

Europe

欧洲

, and established branches in

，并在以下地方设立分支机构

Boston

波士顿

,

，

Philadelphia

费城

,

，

San Diego

圣地亚哥

and

和

London

伦敦

. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification..

三友与全球1000多家制药企业、药物研发机构和诊断公司建立了友好的业务关系。三友荣获国家级高新技术企业、专精特新企业认证，通过ISO9001质量保证体系认证和GB/T知识产权管理体系认证。

SOURCE Sanyou Bio

来源：三友生物

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用